GlassScriptPhysician profile
William Augustus Hays
NPI 1003827858
$9,551.44
in general payments reported to CMS, 2019-2025
47 companies · $1,831 in 2025
The $1,831 reported for 2025 was more than what 93% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,163 · 2020: $1,186 · 2021: $1,250 · 2022: $1,227 · 2023: $1,414 · 2024: $1,480 · 2025: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,724.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,834.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $997.08 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $955.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $760.65 | 2020-2025 | |
| Pfizer INC. | $545.24 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $474.45 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $362.49 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.48 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $316.54 | 2019-2023 | |
| Amarin Pharma, INC. | $296.70 | 2019-2023 | |
| Amgen INC. | $274.77 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbott Laboratories | $269.09 | 2019-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $221.15 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $208.86 | 2019-2022 | |
| Esperion Therapeutics, INC. | $172.94 | 2020-2025 | Nexletol |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hays listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.